Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic Inc. (NASDAQ: HOLX) is a leading global healthcare company dedicated to the science of sure. Headquartered in Bedford, Massachusetts, Hologic specializes in developing, marketing, and servicing some of the most innovative and accurate diagnostic imaging systems and surgical products available today. The company's core business focuses on meeting the healthcare needs of women, operating through five primary segments: diagnostics, breast health, surgical, and skeletal health.
Diagnostics, which accounts for 60% of total sales, has seen a significant boost due to the pandemic, underscoring the company's strategic pivot toward commercial diagnostics following the acquisition of Gen-Probe. This segment includes a wide range of tests and instruments essential for early disease detection and management.
Breast Health, traditionally a cornerstone of Hologic’s business, contributes 14% to total sales. Though this segment was initially suppressed by the pandemic, it remains vital for innovations in mammography and breast surgery. Hologic's Surgical segment, representing 11% of sales, offers advanced products that enhance surgical outcomes and patient safety. The Skeletal Health segment, although smaller at 1% of total sales, provides critical tools for assessing bone health.
Hologic’s reach is vast, with the United States accounting for 69% of its revenue, followed by Europe at 20%, Asia at 8%, and other international markets making up the remaining 3%. The company's diverse, dedicated, and creative team is committed to not only advancing medical science but also providing greater confidence and peace of mind in diagnosis, enabling healthier lives worldwide.
Stay updated with the latest from Hologic by connecting on Hologic.com, Facebook, and Twitter.
Hologic's Global Women's Health Index reveals concerning trends in women's health worldwide. For the first time, cancer testing among women has declined to just 10%, dropping two percentage points from previous years. The report, based on interviews with over 146,000 people across 142 countries, shows that 38% of women faced food insecurity, while 32% struggled with shelter costs.
The global women's health score remains stagnant at 53 out of 100. Taiwan leads with 68, followed by Kuwait (67), Austria (66), and Switzerland (65). The US scored 60, ranking 37th globally. Key findings include increased rates of worry (42%) and sadness (30%) among women, with 35% feeling unsafe in their communities. The study also revealed low HIV testing rates globally at 6%, with some Middle Eastern and North African countries showing rates below 0.5%.
Hologic (HOLX) reported preliminary Q1 FY2025 revenues of $1,021.8 million, showing a 0.9% increase year-over-year, or 1.0% in constant currency. The company expects GAAP and non-GAAP earnings per share to be near the high end of guidance ranges despite currency headwinds that reduced revenue by approximately $9 million.
Division performance showed mixed results: Diagnostics grew 5.1% to $470.6 million, with organic growth excluding COVID-19 at 9.0%. Breast Health declined 2.3% to $369.1 million, while GYN Surgical increased 2.5% to $166.3 million. Skeletal Health saw a significant decline of 37.8% to $15.8 million. The company plans to provide full financial results and updated guidance for Q2 and full-year FY2025 on February 5, 2025.
Hologic (NASDAQ: HOLX) has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference scheduled for Tuesday, January 14, 2025, at 1:30 p.m. Pacific Time. The event will feature both a presentation and Q&A session, which will be accessible through a live webcast.
Interested parties can access the webcast through a link on the Investors section of Hologic's website at http://investors.hologic.com. The webcast recording will remain available for 30 days after the event. Hologic is known for its focus on improving women's health and well-being through early detection and treatment technologies.
Hologic (NASDAQ: HOLX) has scheduled the release of its first quarter fiscal 2025 financial results for Wednesday, February 5, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results.
Participants can join the call by dialing (888) 394-8218 in the US and Canada or +1 (773) 305-6853 for international callers, using access code 4103504. A webcast replay will be available on the company's investor relations website for 30 days following the call.
Hologic (HOLX) has completed its previously announced acquisition of Gynesonics, a private medical device company, for approximately $350 million. The acquisition brings the Sonata System into Hologic's portfolio, expanding their range of minimally invasive solutions for heavy periods and fibroids.
The Sonata System is a technology for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids. It combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in an incisionless procedure. The system has already been used to treat thousands of women, according to Gynesonics' CEO Skip Baldino.
Hologic (NASDAQ: HOLX) has entered into an agreement with the CDC to develop analyte specific reagents (ASRs) for detecting H5N1 bird flu. The development comes as H5N1 continues to spread among wild birds, causing outbreaks in poultry and dairy cows in the U.S. The ASRs will be developed on the Panther Fusion® system, with over 1,700 systems installed across U.S. laboratories.
While Hologic doesn't currently plan to commercialize these ASRs, future commercialization may be considered if rapid H5N1 testing becomes necessary. The Panther systems can generate over 1,000 results in 24 hours and can quickly scale up testing capacity. This initiative builds on Hologic's diagnostic solutions portfolio, including their successful COVID-19 testing programs which shipped over 68 million tests to 40 countries in 2020.
Hologic (HOLX) has responded to the United States Preventive Services Task Force (USPSTF) draft guidelines for cervical cancer screening. The company emphasizes the importance of combining Pap and HPV testing as the gold standard for cervical cancer detection. Cervical cancer mortality rates have decreased by 70% due to screening programs, though incidence rates have plateaued and disproportionately affect Black and Hispanic women.
Multiple studies show that screening women ages 30-65 with combined Pap and HPV testing identifies more cervical pre-cancer and cancer than single tests. The draft guidelines support three screening strategies, including Pap testing for women ages 21-29, and maintain flexibility for shared decision-making between healthcare providers and patients.
Hologic (HOLX) announced the election of Dr. Martin Madaus to its Board of Directors, effective December 6, 2024. Dr. Madaus brings over 30 years of diagnostics and life sciences industry experience to the board. He currently serves as an Operating Executive at the Carlyle Group, which he joined in February 2019.
Dr. Madaus previously held positions as Chairman and CEO of Ortho Clinical Diagnostics, and served as Chairman, President and CEO of Millipore until its acquisition by Merck KGaA in 2010. He will serve on both the Compensation Committee and the Nominating and Corporate Governance Committee.
Four new studies about the Breast Cancer Index (BCI) test will be presented at the 2024 San Antonio Breast Cancer Symposium. The main study investigates BCI's potential to identify postmenopausal women with HR+ early-stage breast cancer who have minimal risk of distant recurrence.
The research validated an adjusted BCI prognostic model that identified a 'minimal risk' group with less than 5% 10-year distant recurrence risk. In the Stockholm and NCR studies, 20% and 16% of patients were identified as minimal risk, with 10-year distant recurrence risks of 2.3% and 4.5%, respectively.
The BCI test is currently recognized by NCCN and ASCO guidelines as the only test predicting which HR+ early-stage breast cancer patients may benefit from extended endocrine therapy beyond five years.
Hologic (NASDAQ: HOLX) presented new research demonstrating its Genius AI Detection 2.0 software performs consistently across diverse patient populations. The study evaluated over 7,500 digital breast tomosynthesis cases from women of different racial/ethnic backgrounds, showing similar performance across all groups. The company also announced the introduction of its next-generation Genius AI Detection PRO solution for the U.S. market, featuring improved accuracy, efficiency, and advanced capabilities including deep-learning algorithms, intuitive scoring, and an all-in-one interface with breast density scoring.
FAQ
What is the current stock price of Hologic (HOLX)?
What is the market cap of Hologic (HOLX)?
What does Hologic Inc. specialize in?
Where is Hologic Inc. headquartered?
What are the main segments of Hologic’s business?
Which segment contributes the most to Hologic's revenue?
How has the pandemic affected Hologic’s business segments?
What percentage of Hologic’s revenue comes from the United States?
How did the acquisition of Gen-Probe impact Hologic?
How can I stay updated with Hologic's latest news?
What is Hologic’s approach to healthcare?
What percentage of Hologic’s revenue comes from international markets?
